



HAL
open science

Psychedelic drugs: more emphasis on safety issues

Florian Naudet, Eiko Fried, Lisa Cosgrove, Erick Turner, Alain Braillon,
Ioana Cristea

► **To cite this version:**

Florian Naudet, Eiko Fried, Lisa Cosgrove, Erick Turner, Alain Braillon, et al.. Psychedelic drugs: more emphasis on safety issues. *Nature*, 2022, 611 (7936), pp.449-449. 10.1038/d41586-022-03680-x . hal-03956255

HAL Id: hal-03956255

<https://univ-rennes.hal.science/hal-03956255>

Submitted on 25 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Psychedelic drugs: more emphasis on safety issues

Florian Naudet, University of Rennes, Rennes, France.

Eiko I. Fried, Leiden University, Leiden, The Netherlands.

Lisa Cosgrove, University of Massachusetts Boston, Boston, Massachusetts, USA.

Erick Turner, Oregon Health & Science University, Portland, Oregon, USA.

Alain Braillon, Amiens, France.

Ioana A. Cristea, University of Padua, Padua, Italy.

Psychedelic drugs have safety issues that are linked with effects such as hallucinations, paranoia and mood changes. In our view, your editorially independent articles on these drugs — sponsored by the biotechnology firm Atai Life Sciences — should have given more attention to such concerns to avoid serving an industry-friendly narrative that could do more harm than good (see www.nature.com/collections/edcbibiadj).

For example, the article on psilocybin for pain relief (*Nature* 609, S100–S102; 2022) notes that researchers are trying to avoid the mistakes that contributed to the opioid crisis. But there are strong parallels: prescription of psychedelics and of opioids is rising as a result of aggressive marketing, whereas the evidence for effectiveness comes mostly from small, short-term trials involving highly selected patients in secure settings, without adequate comparators. And attention to safety issues such as tolerance and drug dependence is crucial, particularly over the long term.

The US Food and Drug Administration has designated many psychedelics as a ‘breakthrough therapy’, in effect lowering the bar for approval. Esketamine, for example, was controversially approved for treatment-resistant depression without adequate monitoring to assess its long-term harm-to-benefit ratio (E. H. Turner *Lancet Psychiatry* 6, 977–979; 2019).

Competing Interests

F.N., L.C., E.T., A.B. and I.A.C. are among those on the LowN List of industry independent experts. E.T. is a former FDA reviewer.